Valuation: Jade Biosciences, Inc.

Market Cap 1.16B 1.02B 951M 873M 1.64B 112B 1.67B 11.3B 4.41B 55.14B 4.37B 4.28B 191B P/E 2026 *
-7.54x
P/E 2027 * -7.61x
Enterprise Value 911M 800M 744M 683M 1.28B 87.74B 1.3B 8.84B 3.45B 43.14B 3.42B 3.35B 149B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day+1.35%
1 week-5.03%
Current month-10.85%
1 month-9.54%
3 months-20.70%
6 months+30.50%
Current year+28.39%
1 week 19.02
Extreme 19.02
21.5
1 month 19.02
Extreme 19.02
23.36
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 50 28/04/2025
Director/Board Member 42 28/04/2025
Chairman 57 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/6/26 Free

Director

47,675 0.0966%
9/6/26
Fairmount Funds Management LLC
FreeCompany 34,843 0.0706%
9/6/26 Free

Director

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
+1.35%-5.03%+137.82% - 1.16B
+1.07%-3.49%-3.25%+12.87% 46.35B
-0.80%+0.43%+402.30%+620.72% 40.13B
+0.05%+4.81%+10.31%+67.50% 36.33B
+1.02%+1.61%+4.36%-8.14% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+0.84%-2.70% - - 16.66B
+0.37%+12.88%+33.21%+145.81% 16.91B
+0.42%-5.52%+0.76%+8.50% 13.05B
-1.69%-1.63%-14.25%-31.08% 13.05B
Average +0.60%+0.49%+63.89%+106.38% 24.5B
Weighted average by Cap. +0.58%+0.75%+75.16%+135.48%

Financials

2026 *2027 *
Net sales - -
Net income -173M -152M -141M -130M -244M -16.68B -248M -1.68B -656M -8.2B -650M -636M -28.35B -191M -168M -156M -143M -269M -18.41B -273M -1.85B -724M -9.05B -718M -702M -31.29B
Net Debt -254M -223M -207M -190M -357M -24.41B -363M -2.46B -961M -12B -952M -931M -41.5B -300M -264M -245M -225M -423M -28.92B -429M -2.91B -1.14B -14.22B -1.13B -1.1B -49.15B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
25/07/26 USD 19.82 +1.02% 340,681
23/07/26 USD 19.62 -1.16% 385,490
22/07/26 USD 19.85 -3.31% 782,830
21/07/26 USD 20.53 +4.37% 910,234
20/07/26 USD 19.67 -5.70% 626,415
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19.62USD
Average target price
48.50USD
Spread / Average Target
+147.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock